Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $596

Vertex Pharmaceuticals Incorporated +0.64% Pre

Vertex Pharmaceuticals Incorporated

VRTX

446.78

446.78

+0.64%

0.00% Pre
Morgan Stanley analyst Terence Flynn maintains Vertex Pharmaceuticals (NASDAQ: VRTX) with a Overweight and raises the price target from $570 to $596.